The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of high-dose chemotherapy and autologous stem cell transplantation (autoSCT) for relapsed/refractory (R/R) primary mediastinal large B-cell lymphoma (PMBCL), a rare type of diffuse large B-cell lymphoma (DLBCL). A single-center experience found that patients treated with rituximab-vorinostat/gemcitabine/busulfan/melphalan (R-vorinostat/GemBuMel) had superior event-free survival (EFS) and overall survival (OS) to those receiving rituximab-BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning prior to autoSCT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Affimed, Astra Zeneca, Secura Bio
